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Abstract
Purpose The naturally-occurring omega-3 polyunsaturated fatty acid eicosapentaenoic acid (EPA) is safe, well-tolerated and 
inexpensive, making it an attractive anti-cancer intervention. However, EPA has only modest anti-colorectal cancer (CRC) 
activity, when used alone. Both cyclooxygenase (COX) isoforms metabolise EPA and are over-expressed in CRC cells. We 
investigated whether COX inhibition increases the sensitivity of CRC cells to growth inhibition by EPA.
Methods A panel of 18 human and mouse CRC cell lines was used to characterize the differential sensitivity of CRC cells to 
the growth inhibitory effects of EPA. The effect of CRISPR-Cas9 genetic deletion and pharmacological inhibition of COX-1 
and COX-2 on the anti-cancer activity of EPA was determined using in vitro and in vivo models.
Results Genetic ablation of both COX isoforms increased sensitivity of CT26 mouse CRC cells to growth inhibition by EPA 
in vitro and in vivo. The non-selective COX inhibitor aspirin and the selective COX-2 inhibitor celecoxib increased sensitiv-
ity of several human and mouse CRC cell lines to EPA in vitro. However, in a MC38 mouse CRC cell tumour model, with 
dosing that mirrored low-dose aspirin use in humans, thereby producing significant platelet COX-1 inhibition, there was 
ineffective intra-tumoral COX-2 inhibition by aspirin and no effect on EPA sensitivity of MC38 cell tumours.
Conclusion Cyclooxygenase inhibition by non-steroidal anti-inflammatory drugs represents a therapeutic opportunity to 
augment the modest anti-CRC activity of EPA. However, intra-tumoral COX inhibition is likely to be critical for this drug-
nutrient interaction and careful tissue pharmacodynamic profiling is required in subsequent pre-clinical and human studies.
Keywords Aspirin · Cancer pharmacology · Celecoxib · Colorectal cancer · Cyclooxygenase · Drug metabolism · 
Eicosapentaenoic acid
Introduction
Omega-3 polyunsaturated fatty acid (O3FA) supplements 
containing eicosapentaenoic acid (EPA) and docosahexae-
noic acid (DHA) are safe, well-tolerated, with beneficial 
cardiovascular effects [1, 2] and anti-inflammatory proper-
ties [3]. Pure EPA is licensed for use in severe hypertri-
glyceridemia and has been shown to reduce major cardio-
vascular and cerebrovascular events in high-risk individuals 
[4]. Oral EPA [2 g free fatty acid (FFA) daily] has modest 
primary colorectal cancer (CRC) chemoprevention activity 
in familial adenomatous polyposis (FAP) and in individu-
als with ‘sporadic’ colorectal adenomas [5, 6]. O3FAs also 
have the potential for the treatment of CRC [7]. We have 
previously shown that EPA inhibits the growth of synge-
neic CT26 mouse CRC cell liver tumours in an intra-splenic 
injection model of CRC liver metastasis (LM) in BALB/c 
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mice [8], at levels of tumour EPA incorporation attained in 
randomised controlled trials (RCTs) [5, 6]. A phase 2 RCT 
of EPA 2 g FFA daily in patients awaiting liver resection sur-
gery for CRCLM (the EMT trial) showed that EPA was safe 
and well-tolerated in advanced CRC patients [9]. The EMT 
trial suggested possible overall survival benefit from EPA 
for 12–18 months after surgery [9] and has led to the phase 
3 EMT2 RCT of long-term treatment with EPA in patients 
undergoing CRCLM surgery (NCT03428477).
Human CRC cells display differential sensitivity to EPA 
in vitro. In some cell lines, 50 µM EPA or below is sufficient 
to have anti-proliferative effects [9–12]. Yet, 150 µM EPA or 
above is necessary to induce significant growth inhibition in 
others [13]. Differential sensitivity to EPA is also observed 
in other cancer cell types with 5–10 µM EPA reported to 
inhibit the growth of three human pancreatic cancer cell 
lines [14].
Several mechanisms of action of the anti-CRC activity 
of EPA have been proposed, including lipid raft modulation 
and altered metabolism by cyclooxygenase (COX)-1 and -2, 
lipoxygenases and CYP450 monooxygenases [14–17].
We exploited differential sensitivity of CRC cells to EPA 
to delineate factors controlling resistance to EPA, with a 
view to optimising anti-cancer treatment with this O3FA. 
We identified the COX isoforms as mediators of CRC cell 
resistance and tested the hypothesis that COX inhibition, 
which is a clinically relevant intervention using available 
non-steroidal anti-inflammatory drugs (NSAIDs), increases 
CRC cell sensitivity to the growth inhibitory effects of EPA.
Methods
Materials
Pure EPA-FFA, a gift from SLA Pharma (UK) was used for 
in vitro experiments [18]. For animal diets, we used 90% 
EPA-triglyceride (TG) oil (Ingennus Healthcare Nutrition, 
UK) [6]. Aspirin and celecoxib were purchased from Sigma-
Aldrich (UK). A working stock solution of aspirin (50 mg/
ml) and celecoxib (5 mM) for in vitro use was made in abso-
lute ethanol and dimethyl sulphoxide, respectively.
CRC cell lines
CT26 and  COXlow-CT26 (CRISPR-Cas9 targeted deletion 
targeting Ptgs1 and Ptgs2) mouse CRC cells were a gift from 
Dr Santiago Zelenay (Cancer Research UK Institute, Man-
chester, UK) [19]. MC38 mouse CRC cells were a gift from 
Professor Daniel Beauchamp (Vanderbilt University, TN) 
[20], from which we isolated a motile, EPA-resistant sub-
population of MC38 cells, termed MC38r, using transform-
ing growth factor (TGF)β (5 ng/ml) as a chemoattractant in 
a  Transwell® migration assay. MC38r cells have remained 
phenotypically stable during multiple passages over sev-
eral years (Online Resource 1). All human CRC cells were 
obtained from the ATCC (https ://www.atcc.org), except 
TC71 cells, which were a gift from Professor Alex Duval 
(INSERM, France). Human CRC cell lines were authenti-
cated by STR profiling. All cell lines were tested regularly 
for Mycoplasma infection.
Gene expression microarray analysis
Total RNA (100 ng) was processed according to the Illu-
mina Whole-genome Gene Expression Direct Hybridization 
Assay Guide before 1.5 μg of cRNA was hybridised to a 
Mouse WG-6_v2 Beadchip as technical triplicates. Array 
1 (Geo/GSE135607) compared gene expression in MC38 
cells treated with 50 μM EPA-FFA for 24 h compared with 
MC38 cells exposed to the same dilution of ethanol (0.15% 
v/v) only. Array 2 (Geo/GSE135135) compared basal gene 
expression levels between MC38r and MC38 cells. Illumina 
GenomeStudio software v2010.2 and Ingenuity Pathway 
 Analysis® (December 2013 version) were used for data 
analysis.
MTT assay
Cell sensitivity to EPA-FFA, aspirin and celecoxib was 
determined using the 3-(4,5-dimethylthiazol-2-yl)-2,5-di-
phenyltetrazolium bromide (MTT) cell viability assay [21]. 
Cells were incubated for 96 h with test agents, alone and 
in combination. The half-maximal inhibitory concentra-
tion  (IC50) was calculated using either variable slope or 
biphasic equations in Prism6™ (GraphPad Software) and is 
expressed as the mean ± standard error of the mean (SEM).
COX protein expression in mouse CRC cells
Total protein lysates (100 µg) were analysed by Western 
blotting using goat polyclonal antibodies against COX-1 (sc-
1752, 1/250) and COX-2 (sc-1745, 1/250; both Santa Cruz, 
USA), as well as mouse monoclonal anti-β-actin antibody 
(clone AC-15, 1/10,000; Sigma-Aldrich, UK), incubated 
overnight at 4 °C. Secondary antibodies (1/2000, DakoCy-
tomation, UK) were used for one hr at ambient temperature 
prior to visualisation using Supersignal West Pico Chemi-
luminescence (Pierce, UK).
Real‑time reverse transcription‑polymerase 
chain reaction (RT‑qPCR) measurement of PTGS1 
and PTGS2 transcript levels
Total RNA was extracted using the RNeasy Micro kit (QIA-
GEN, UK). and then treated with DNase I (New England 
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Biolabs, UK). cDNA synthesis was performed with 1 μg 
of total RNA input using the Omniscript RT kit (QIAGEN, 
UK). Real-time PCR was performed using GoTaq qPCR 
mastermix (Promega, UK) and the following primers, 
PTGS1: forward 5′-GAG CAG CTT TTC CAG ACG A-3′ and 
reverse 5′-TCC TCG ATG ACA ATC TTG ATG-3′, PTGS2: 
forward 5′-CCC TTG GGT GTC AAA GGT AA-3′, reverse 
5′-GCC CTC GCT TAT GAT CTG TC-3′ and GAPDH: forward 
5′-TCA ACG ACC ACT TTG TCA AGC-3′ and reverse 5′-CCA 
GGG GTC TTA CTC CTT GG-3′. Relative quantification using 
ThermoFisher Connect™ generated a gene expression score 
for COX-1 and COX-2 according to the respective ∆Ct value 
 [Ct(PTGS) −  Ct(GAPDH)] tertile [zero for no expression (as 
defined by the absence of a  Ct(PTGS) value below that asso-
ciated with background), or 1–3]. The overall COX score 
for each cell line was determined by summing COX-1 and 
COX-2 scores. Data are expressed as the mean ± SEM of 
three biological replicates for each human CRC cell line.
In vivo studies
Female CD1 Nude and BALB/c mice (Charles River Labo-
ratories, UK) were housed in a specific pathogen-free envi-
ronment. All experiments were undertaken with UK Home 
Office approval. Five-week-old mice were provided with 
isocaloric diets ad libitum for 14 days. Diets were based 
on a modified AIN-93G diet base, in which 7% (w/w) soy-
bean oil was replaced by corn oil. EPA-TG {6.1% (w/w); 
equivalent to 5% (w/w) EPA-FFA content, for which we have 
previously demonstrated anti-CRC activity [8, 22]} replaced 
the equivalent amount of corn oil in EPA-containing diets. 
Aspirin-containing diets included either 200 parts per mil-
lion (ppm), 400 ppm or 600 ppm aspirin. Experimental diets 
were manufactured by Safe (France), delivered in vacuum-
packed 1 kg bags and stored at 4 °C to minimize oxidation. 
Food was replaced every 3–4 days, during which time there 
was no increase in lipid oxidation from baseline values as 
shown by dedicated stability testing (Online Resource 2). 
For subcutaneous tumour models,  107 cells were injected 
subcutaneously into the flank of each CD1 Nude mouse 
on day 15. Animals continued on the same diet for a fur-
ther 14 days until sacrifice. Tumour volume in  mm3 (π/6 × 
[length ×  width]3/2) was measured using calipers. For the 
CRCLM model, 5 × 106 CRC cells in 100 µl sterile PBS were 
introduced into the spleen by high-frequency ultrasound-
guided injection (VEVO770, VisualSonics Inc., Canada) 
under isofluorane anaesthesia [8]. Mice continued on the 
same diet for a further 14 days until sacrifice. Tumour bur-
den was determined by measuring liver weight at a sacrifice. 
Tissue samples were either fixed in 4% (w/v) paraformal-
dehyde in PBS overnight, prior to embedding in paraffin 
or were snap-frozen in liquid  N2 before storage at − 80 °C. 
Urine and blood samples were also collected at a sacrifice. 
Serum was obtained after allowing the blood to clot at room 
temperature for 30 min, centrifugation at 2000g for 10 min 
at 4 °C, before storage at − 80 °C.
Eicosanoid and fatty acid measurement
6-Keto-prostaglandin (PG)  F1α, 11-dehydro-thromboxane 
(TX)  B2,  TXB2 and  PGE2 levels were measured by specific 
immunoassays (Cayman Chemical, US).
Fatty acids were measured by liquid chromatogra-
phy-electrospray ionization-tandem mass spectrometry 
(LC–ESI–MS/MS), as described previously [23]. Fatty 
acid levels are reported as the % of the total fatty acid con-
tent. For chiral analysis of 15-hydroxyeicosatetraenoic acid 
(HETE), HCA-7 human CRC cells were treated for 30 min 
with 500 µM aspirin (or equivalent DMSO control car-
rier) before the cell-conditioned medium was removed and 
refreshed with added 1 µM C20:4n6 arachidonic acid (AA) 
(or the equivalent v/v dilution of ethanol) for a further three 
hrs. Conditioned media were collected and analysed for 
15-HETE by chiral LC–ESI–MS/MS, as described previ-
ously [24].
Immunohistochemistry for COX‑1 and COX‑2
Sections (5 µm) were dewaxed and rehydrated before antigen 
retrieval (Access Revelation solution, Menarini Diagnostics, 
UK). Following a peroxidase block (Menarini Diagnostics), 
slides were blocked in casein solution (Menarini Diagnos-
tics) and then incubated for 1 h at room temperature with 
either goat polyclonal anti-COX-1 (sc-1752, 1/100, Santa 
Cruz), or rabbit polyclonal anti-COX-2 (160162, 1/5, Cay-
man Chemical, UK) antibody, followed by addition of 
Impress™ Goat polymer or Impress™ Rabbit polymer (Vec-
tor Laboratories, UK) and DAB solution (Biocare Medical, 
UK), before counterstaining. Staining score of whole sec-
tions was determined by 2 independent observers blinded to 
treatment allocation on a scale of 0–2 for COX-1 and 0–3 for 
COX-2 (Online Resource 3, supplementary fig. S1).
Results
Differential sensitivity of human and mouse CRC 
cells to EPA
We performed a comprehensive screen of EPA sensitivity 
of 16 human and 2 mouse CRC cell lines using an MTT 
cell viability assay. Human and mouse CRC cell lines dis-
played a range of sensitivity to EPA in vitro, with  IC50 values 
ranging from 38.0 ± 3.4 µM (MC38 mouse CRC cells) to 
241.8 ± 1.1 µM (CT26 mouse CRC cells; Fig. 1 and Online 
Resource 3—supplementary fig. S2). Several human CRC 
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cell lines, including HRT18 and HT29 cells, exhibited a 
biphasic concentration–response relationship with EPA, 
which was evident as two distinct concentration–response 
phases separated by a plateau that was confirmed by regres-
sion analysis, suggesting that EPA may act via two separate 
mechanisms in some CRC cell lines (Online Resource 3—
supplementary fig. S2). The EPA-sensitive mouse CRC cell 
line MC38 also displayed a biphasic response to EPA with 
component  IC50 values of 10.5 ± 1.9 µM and 141.2 ± 1.3 µM 
(Online Resource 3—supplementary fig. S2).
COX enzymes mediate EPA resistance in mouse CRC 
cells
Relative EPA sensitivity of MC38 mouse CRC cells pro-
vided an opportunity to isolate EPA-resistant cells from the 
overall MC38 cell population. These cells, termed MC38r, 
were greater than 4-fold more resistant to EPA than paren-
tal MC38 cell cultures (Fig. 2a) and had lost the biphasic 
concentration–response displayed by MC38 cells (Fig. 2a). 
Relative EPA resistance of MC38r cells has been maintained 
for more than 30 passages (Online Resource 1), without 
selection pressure from exogenous EPA.
Differential gene expression analysis was performed 
using two whole-genome microarrays, which tested the 
effect of EPA exposure on MC38 cell gene expression (array 
1) and compared basal gene expression in MC38r and MC38 
cells (array 2). The full lists of differentially expressed genes 
are available in the Geo database. The highest differentially 
expressed genes included Lox, Col6a1 and P4ha1, which are 
all linked to epithelial-mesenchymal transition and migra-
tion, likely resulting from the selection for the migratory 
phenotype of MC38r cells (Online Resource 4). The next 
three genes encoded an orphan G protein-coupled receptor 
(MRGPRF), a protein mediating inflammatory signalling 
(ANGPTL6), and COX-1 (Online Resource 4). There was 
no change in Ptgs1 gene expression in upon MC38 expo-
sure to EPA, however, its expression was increased 3.2-fold 
in the EPA-resistant MC38r cells compared to MC38 cells. 
Given existing data linking EPA activity and modulation of 
COX activity [25], we examined the expression of COX-1 
and COX-2 proteins in MC38 and MC38r cells by western 
blotting. MC38r cells displayed an increase in COX-1 and 
COX-2 protein levels compared with MC38 cells (Fig. 2b), 
which was associated with a statistically significant increase 
in  PGE2 production by MC38r cells compared with MC38 
cells (Fig. 2c).
We next investigated whether there was a causal rela-
tionship between COX activity and CRC cell resistance 
to EPA. We examined a pair of isogenic mouse CRC cell 
lines; CT26, which is relatively resistant to EPA (Fig. 1), and 
 COXlow-CT26, in which expression and activity of both COX 
isoforms are reduced by CRISPR/Cas9 editing [19], thereby 
providing a genetic model of dual, non-selective COX inhi-
bition that is achieved by NSAIDs such as aspirin and ibu-
profen. Reduced COX-1 and COX-2 expression (Fig. 2d) and 
activity (Fig. 2e) in  COXlow-CT26 cells resulted in increased 
sensitivity to EPA  (IC50 148.9 ± 1.2 µM) compared with 
CT26 cells  (IC50 241.8 ± 1.1 µM; p = 0.03, 2-way ANOVA; 
Fig. 2f), thereby supporting the hypothesis that COX-1 and 
COX-2 mediate CRC cell resistance to EPA in vitro.
Reduced COX activity is associated with enhanced 
EPA sensitivity of mouse CRC cell tumours in vivo
We then tested whether reduced COX expression and activ-
ity in CRC cells would increase EPA sensitivity of CRC 
tumours in vivo. We used our established syngeneic BALB/c-
CT26 model of CRCLM [8] to test the impact of oral admin-
istration of EPA on tumour growth. There was no signifi-
cant reduction in  COXlow-CT26 cell tumour burden in mice 
receiving control diet compared with control animals with 
CT26 cell tumours, indicating that reduction of COX expres-
sion by CRC cells does not impact on tumour growth in an 
immunocompetent mouse tumour model (Fig. 3a). Oral EPA 
supplementation was associated with a 10% reduction in 
median liver weight in animals with CT26 cell liver metas-
tases compared with a statistically significant 30% decrease 
in tumour burden (p = 0.05) associated with EPA treatment 
in mice bearing  COXlow-CT26 CRC cell liver metastases 
Fig. 1  Colorectal cancer cell sensitivity to EPA in vitro.  IC50 values 
for EPA after continuous exposure of human and mouse CRC cell 
lines to a range of EPA concentrations for 96  h. Data represent the 
mean ± SEM value for multiple independent replicates as indicated on 
the x axis. Human CRC cell lines are ordered according to decreasing 
mean  IC50 value
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Fig. 2  COX expression mediates EPA sensitivity of CRC cells 
in vitro. a MTT cell viability assay curves for the effect of EPA on 
MC38 (closed circles) and MC38r mouse CRC cells (open circles). 
Data represent the mean ± SEM % growth compared to untreated con-
trol cells for three independent replicates for each mouse CRC cell 
line. b Western blot analysis of COX isoform protein expression in 
MC38 and MC38r mouse CRC cells. c  PGE2 levels in medium con-
ditioned by MC38 and MC38r cells for 24  h. Data compared with 
Student’s t test. d Western blot analysis of COX isoform protein 
expression in CT26 and  COXlow-CT26 mouse CRC cells. e  PGE2 
levels in medium conditioned by CT26 and  COXlow-CT26 mouse 
CRC cells for 24 h. Data compared with Student’s t test. f MTT cell 
viability assay curves for the effect of EPA on CT26 (closed circles) 
and  COXlow-CT26 mouse CRC cells (open circles). Data represent 
the mean ± SEM % growth compared to untreated control cells for 
three independent replicates for each mouse CRC cell line. Two-
way ANOVA confirmed a significant increase in EPA sensitivity of 
 COXlow-CT26 cells compared with CT26 mouse CRC cells (p = 0.03)
Fig. 3  Reduced COX expression increases the sensitivity of mouse 
CT26 CRC cell tumours to EPA in vivo. a CT26 and  COXlow-CT26 
cell liver metastases in BALB/c mice. The horizontal line indicates 
the median liver weight at a sacrifice in each group. The reference 
normal liver weight of female BALB/c mice is 0.99 g (https ://www.
jax.org/). b Subcutaneous CT26 and  COXlow-CT26 cell tumours 
in CD1 Nude mice receiving either control or EPA-containing diet 
(n = 5 per group). The horizontal line indicates the median tumour 
volume at a sacrifice in each group. Statistical significance was tested 
with the Mann–Whitney U test
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(Fig. 3a), despite similar tissue levels of EPA in both tumour 
types (Online Resource 3—supplementary fig. S3a). There-
fore, we concluded that reduced COX-1 and COX-2 activity 
results in increased sensitivity of CT26 mouse CRC cells to 
EPA in vivo.
If COX activity promotes CRC cell resistance to EPA, 
one might expect a relationship between COX-1/COX-2 
expression and EPA sensitivity in individual CRC cell lines. 
No simple relationship between COX mRNA levels and the 
 IC50 value for EPA measured by the MTT assay was evident 
in our large panel of human CRC cell lines (Online Resource 
3—supplementary fig. S4a). Nevertheless, we observed that 
human CRC cell lines that demonstrated a biphasic concen-
tration–response relationship with EPA had, in general, a 
lower COX-2 (not COX-1) score than counterparts with a 
mono-phasic relationship between growth and EPA concen-
tration (Online Resource 3- supplementary fig. S4b). Fur-
thermore, fatty acid analysis of human CRC cell lines treated 
with 5 µM EPA-FFA demonstrated a correlation between the 
fold-increase in % EPA content from baseline values and 
sensitivity to EPA (measured as a lower  IC50 value) in the 
individual human CRC cell lines (Online Resource 3—sup-
plementary fig. S5).
COX enzymes modulate the direct anti‑neoplastic 
activity of EPA on CRC cells
Zelenay and colleagues have reported that COX-2-PGE2 sig-
nalling represses the host anti-tumour response to subcutane-
ous CT26 mouse CRC cell tumours and that COX inhibitors 
have anti-tumour effects in this model through de-repression 
of the adaptive anti-tumour immune response [19]. There-
fore, to determine the relative contributions of (1) modula-
tion of the host anti-tumour immune response and/or (2) 
direct effects on tumour cell resistance by the COX enzymes 
that might contribute to EPA sensitivity of CRC cell tumours 
in vivo, we used CD1 Nude mice, which do not mount a T 
cell-dependent adaptive immune response. Consistent with 
the BALB/c mouse experiments, CT26 and  COXlow-CT26 
tumour tissues incorporated EPA to a similar degree fol-
lowing dietary EPA administration (Online Resource 3- 
supplementary fig. S3b).  COXlow-CT26 cell tumours were 
significantly smaller than CT26 cell tumours suggesting that 
COX activity drives CT26 cell tumour growth directly in this 
subcutaneous tumour microenvironment (Fig. 3b). Dietary 
EPA treatment of CT26 cell tumour-bearing mice resulted in 
a 62% reduction in tumour growth [median tumour volume 
676  mm3 (range 122–2609  mm3)] compared to diet controls 
[1776  mm3 (range 482–3699  mm3)] (Fig. 3b). However, 
EPA supplementation in  COXlow-CT26 cell tumour-bear-
ing animals resulted in a more obvious decrease in tumour 
size, with uniform growth suppression of all subcutaneous 
tumours [median 122  mm3 (range 39–204  mm3)], compared 
with animals that received control diet [398  mm3 (range 
125–1291  mm3), p = 0.07; Fig. 3b]. Consistent with our 
in vitro data, the efficacy of EPA in the immunodeficient 
CD1 Nude mouse model implies that the COX isoforms 
modify the response of tumour cells themselves to EPA 
in vivo, rather than modification of the host anti-tumour T 
cell-mediated immune response.
Aspirin and celecoxib increase CRC cell sensitivity 
to EPA in vitro
Aspirin has known anti-CRC activity and is currently under-
going phase 3 RCT evaluation as an adjunct to standard care 
in individuals with CRC after surgical resection of the pri-
mary tumour (ClinicalTrials.gov NCT02804815) [26, 27]. 
Aspirin irreversibly inhibits COX-1 activity and modifies 
COX-2 activity leading to reduced  PGE2 synthesis [28], thus 
providing dual COX inhibition.
To maximise the effect of aspirin on COX metabolism 
whilst avoiding any non-specific cytotoxic activity against 
CRC cells in vitro, we selected a dose of 500 μM aspirin 
to be used in combination with a range of EPA concentra-
tions (Online Resource 3—Supplementary fig. S6a). Many 
other studies, which have previously investigated the effect 
of aspirin on CRC cell growth in vitro, have used higher 
concentrations of aspirin, often reaching 1–10 mM [29, 
30]. Reduced  PGE2 production in high COX-2-expressing 
MC38r and CT26 cells following 500 µM aspirin exposure 
confirmed effective COX-1 and COX-2 inhibition (Fig. 4a). 
In addition, we confirmed that 500 µM aspirin specifically 
altered COX-2 activity by demonstrating a switch in the 
chirality of the minor COX-2 product 15- HETE from the 
S- to the R-enantiomer that is known to occur after serine 
acetylation of the COX-2 active site, thus confirming the 
pharmacological specificity of our in vitro cell model of 
aspirin-induced COX inhibition (Online Resource 3—sup-
plementary fig. S6b) [31].
Aspirin (500 µM) increased mouse CRC cell sensitivity 
to EPA, as measured by the MTT assay, in each cell line 
except for  COXlow-CT26 cells (Fig. 4b). In the presence 
of aspirin, the  IC50 in MC38 cells was decreased nearly 
two-fold, whilst the  IC50 for MC38r and CT26 cells, which 
express high levels of COX-2, was nearly four-fold lower 
in the presence of aspirin than for EPA alone (Fig. 4b). 
Aspirin restored the biphasic concentration–response 
relationship for EPA, which we had observed in MC38 
cells (Fig. 2a), to MC38r cells (Fig. 4c). In the presence 
of aspirin, CT26 cells also displayed a biphasic concen-
tration–response relationship with EPA, mimicking the 
difference between CT26 cells and  COXlow-CT26 cells 
(Fig. 4d). Three (CaCo2, SW620 and LoVo) of the six 
human CRC cell lines that we examined were more sensi-
tive to EPA in the presence of aspirin by approximately 
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25% (Fig. 4e). The three human CRC cell lines that dis-
played increased EPA sensitivity in the presence of aspi-
rin were all cell lines exhibiting relative EPA resistance 
 (IC50 > 140 µM; Fig. 1).
We also demonstrated that the selective COX-2 inhibitor 
celecoxib, at a concentration (0.5 µM) that inhibited  PGE2 
production by > 90% in mouse CRC cell lines (Fig. 4a) and 
did not display toxicity (Online Resource 3—supplementary 
fig. S7), increased sensitivity of COX-2-expressing mouse 
CRC cells to EPA (Fig. 4b).
One hypothesis is that genetic or pharmacological inhibi-
tion of COX activity increases the sensitivity of CRC cells 
to EPA via a reduction in EPA catabolism and a consequent 
increase in cellular EPA level. Therefore, we investigated 
the effect of aspirin and celecoxib on cellular EPA levels in 
the absence and presence of exogenous EPA. As expected, 
the addition of EPA was associated with an increase in the 
proportion of EPA present in the total fatty acid pool in 
mouse CRC cells (Fig. 4f). It is noteworthy that increased 
COX-2 expression in MC38r cells was associated with 
Fig. 4  Aspirin increases EPA sensitivity of CRC cells in  vitro. a 
 PGE2 synthesis by mouse CRC cells in the presence or absence 
of aspirin (500  µM) or celecoxib (0.5  µM). Data represent the 
mean ± SEM %  PGE2 level of three independent replicates compared 
with control cells. b Mouse CRC cell sensitivity to EPA in the pres-
ence or absence of aspirin (500 µM) or celecoxib (0.5 µM). Data rep-
resent the mean ± SEM  IC50 values for three independent replicates. 
The differences in  IC50 values for the combination treatments com-
pared with EPA alone were statistically significant (Student’s t test 
p < 0.01). c Concentration–response relationship with EPA for MC38 
(closed circles), MC38r (open circles) and aspirin-treated MC38r 
cells (crosses). Data are expressed as the mean ± SEM % growth com-
pared with untreated control cells for three independent experiments. 
d Concentration–response relationship with EPA for CT26 cells 
(closed circles),  COXlow-CT26 cells (open circles) and aspirin-treated 
CT26 cells (crosses). Data are expressed as the mean ± SEM % 
growth compared to untreated control cells for 3 independent experi-
ments. e Response to EPA of human CRC cell lines in the presence 
or absence of aspirin (500 µM). Data represent the mean ± SEM  IC50 
value for 3 independent replicates. The differences in  IC50 values for 
the combination treatments compared with EPA alone were all statis-
tically significant (Student’s t test p < 0.05). f EPA content (expressed 
as the % total fatty acids) of mouse CRC cells with or without the 
addition of 5  µM EPA to the culture medium, in the presence or 
absence of either aspirin (500 µM) or celecoxib (0.5 µM). Data repre-
sent the mean + SEM % EPA level of 3 independent replicates. In the 
absence of an error bar, data represent n = 1 as other samples failed 
analysis for technical reasons
 Cancer Chemotherapy and Pharmacology
1 3
reduced EPA levels compared with MC38 cells (Fig. 4f) 
and that  COXlow-CT26 cells displayed increased EPA lev-
els compared with CT26 cells, which express higher levels 
of COX-1 and COX-2 (Fig. 4f). However, pharmacological 
COX inhibition by either aspirin or celecoxib was not asso-
ciated with an increase in cellular EPA content, even in the 
presence of exogenous EPA (Fig. 4f).
Supplementary fig. S8 (Online Resource 3) demonstrates 
that the mouse CRC cell lines were each capable of conver-
sion of EPA to n-3 docosapentaenoic acid (DPA), but that 
this was not associated with desaturation to DHA or dis-
placement of n-6 arachidonic acid (AA) from the cellular 
fatty acid pool.
We conclude that alteration of cellular EPA levels and/or 
the metabolic fate of EPA is not likely to explain simply how 
a reduction in COX activity by genetic or pharmacological 
means is associated with increased sensitivity of CRC cells 
to EPA.
Anti‑CRC activity of EPA in vivo is not enhanced 
by aspirin dosing that mimics low‑dose aspirin use 
in humans
Prior to testing the effect of aspirin on EPA sensitivity of 
CRC cell tumours in vivo, we confirmed that our mouse 
model reflected the pharmacodynamic profile of low-dose 
(≤ 300 mg daily) aspirin use in humans. A dose-dependent 
reduction in serum  TXB2 level (a measure of platelet COX-1 
inhibition) was evident (Online Resource 3—supplementary 
fig. S9a). Administration of a 600 ppm aspirin-containing 
diet for 9 days was associated with a reduction in serum 
 TXB2 levels of greater than 85% in non-tumour bearing CD1 
Nude mice (median 13.3 ng/ml (range 3.5–51.7 ng/ml) com-
pared with animals that were fed a control diet [122 ng/ml 
(range 31.4–131.5); Online Resource 3—supplementary fig. 
S9a]. This mirrors the percentage reduction in serum  TXB2 
observed in humans following dosing with aspirin 75 mg 
daily [32]. The diet containing 600 ppm aspirin was well tol-
erated based on body weight monitoring (Online Resource 
3—supplementary fig. S9b).
MC38 and MC38r mouse CRC cells were grown as 
subcutaneous tumours in CD1 Nude mice that received 
either control diet, a diet supplemented with 6.1% (w/w) 
EPA-TG alone, 600 ppm aspirin-containing diet, or a diet 
containing both EPA and aspirin (n = 10 each group). We 
confirmed that there was a significant reduction in urinary 
11-dehydro-TXB2 level (indicative of effective systemic 
COX-1 inhibition) at sacrifice in animals treated with aspi-
rin alone compared with controls (Fig. 5a). However, there 
was no significant reduction in urinary 6-keto-PGF1α (the 
stable hydrolysed product of COX-2-derived endothelial 
cell  PGI2 production) levels associated with administration 
of 600 ppm aspirin-containing diet for 28 days (Fig. 5a), 
suggesting ineffective systemic COX-2 inhibition in CD1 
Nude mice, which is consistent with the pharmacodynamic 
profile of low-dose aspirin use in humans [33].
Dietary EPA supplementation alone resulted in a signifi-
cant reduction in MC38 cell tumour volume [median 297 
 mm3 (range 62–918  mm3)] compared with control tumours 
[699  mm3 (range 116–974  mm3); p = 0.03; Fig. 5b]. Addi-
tion of aspirin to the EPA-containing diet did not further 
reduce MC38 cell tumour size compared with EPA alone 
(Fig. 5b). Treatment with EPA alone did not reduce MC38r 
cell tumour volume (p = 0.15; Fig. 5c), but combined treat-
ment with EPA and aspirin did result in a significant reduc-
tion in MC38r tumour volume [median 455  mm3 (range 
146–980  mm3)] compared with tumours from mice that 
received control diet [median 699  mm3 (range 400–1258) 
 mm3; Fig. 5c]. However, this was indistinguishable from the 
MC38 tumour sizes observed in mice treated with aspirin 
alone (Fig. 5c). Levels of EPA measured in control and EPA-
treated MC38 and MC38r cell tumours were comparable 
(Online Resource 3—supplementary fig. S10). The com-
bination of aspirin and EPA was associated with a statisti-
cally significant increase (p = 0.01) in tumour EPA content 
compared with EPA alone in MC38 cell tumours, but not 
MC38r cell tumours (Online Resource 3—supplementary 
fig. S10). In keeping with dominant inhibition of COX-1 
activity by aspirin, compared with COX-2, in the CD1 Nude 
mouse model, intra-tumoral  PGE2 levels were reduced only 
partially by aspirin in both MC38 and MC38r cell tumours 
(Fig. 5d, e), with an attenuated, statistically insignificant 
response in MC38r cell tumours, in which COX-2-depend-
ent  PGE2 synthesis is increased (Fig. 5d, e). Reduction in 
tumour  PGE2 levels was not explained by decreased COX-1 
and COX-2 protein levels, as there was no significant dif-
ference in expression of either COX-1 or COX-2 protein in 
either MC38 or MC38r cell tumours in any of the treatment 
groups (Fig. 5f). We conclude that treatment with aspirin, in 
a mouse model mimicking low-dose aspirin use in humans, 
does not increase the sensitivity of CRC cell tumours to 
EPA, in direct contrast to the effects seen in vitro.
We also tested the effect of aspirin co-treatment on human 
CRC cell sensitivity to EPA in vivo. We examined SW620 
and HCA-7 human CRC cell xenograft tumours in CD1 
Nude mice as exemplar EPA-resistant and -sensitive human 
CRC cell lines, which both displayed similar sensitivity to 
EPA as their in vitro  IC50 values would suggest (Figs. 1, 4e), 
with faster-growing SW620 cell tumours being resistant to 
EPA-TG treatment alone (Fig. 6a) compared with HCA-7 
cell tumours (Fig. 6b), despite similar EPA incorporation 
in each tumour-type when animals were provided with an 
EPA-containing diet (Online Resource 3—supplementary 
fig. S11). In both CRC cell models, aspirin treatment alone 
reduced tumour growth, with no additional benefit of com-
bined EPA and aspirin treatment observed (Fig. 6).
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Fig. 5  Aspirin treatment does not improve MC38 CRC cell tumour 
response to EPA in a mouse model that mimics low-dose aspirin use 
in humans. a Effect of oral aspirin dosing on levels of the urinary 
metabolites 11-dehydro-TXB2 and 6-keto-PGF1α in CD1 Nude mice 
with MC38 cell (black circles) or MC38r cell (grey circles) tumours. 
Urine was not obtained from all animals. The horizontal line indi-
cates the median value for each group. Statistical significance was 
tested using the Mann–Whitney U test. b MC38 cell and c MC38r 
cell tumour volume in CD1 Nude mice receiving diets containing 
either EPA-TG (6.1%), aspirin (600 ppm), or a combination of EPA 
and aspirin, or control diet (n = 14 per group). The line indicates the 
median value for each group. Statistical significance was tested using 
the Mann–Whitney U test. d MC38 cell and e MC38r cell tumour 
 PGE2 levels in animals fed either control or aspirin-containing diet. 
The line indicates the median value for each group. f COX-1 and 
COX-2 protein expression measured by immunohistochemistry in 
MC38 and MC38r tumours. The bars delineate the range of IHC 
scores obtained within a group and the bold line indicates the median 
score for each group
Fig. 6  Effect of EPA and aspirin on human CRC cell tumour growth 
in vivo. a SW620 and b HCA-7 human CRC cells were grown as sub-
cutaneous tumours in CD1 Nude mice provided with a control diet 
or a diet containing either EPA (6.1%), aspirin (600 ppm) or a com-
bination of EPA and aspirin (n = 5 per group). The line indicates the 
median tumour volume for each group
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Discussion
We demonstrate that COX-1 and COX-2 drive EPA resist-
ance of CRC cells and that the widely used, non-selec-
tive COX inhibitor aspirin and selective COX-2 inhibitor 
celecoxib mirror the effect of genetic ablation of COX-1 
and COX-2 by sensitising multiple human and mouse CRC 
cell lines to EPA in vitro. Previous reports have demon-
strated that the combination of an O3FA with a COX 
inhibitor in vitro provides synergistic anti-neoplastic ben-
efit. For example, a combination of the selective COX-2 
inhibitor celecoxib and DHA led to decreased proliferation 
and increased apoptosis of HCA-7 human CRC cells [34]. 
Moreover, combined DHA and sulindac (a non-selective 
COX inhibitor) treatment decreased growth and increased 
apoptosis of three human CRC cell lines compared with 
either agent alone [35].
Aspirin dosing in our CD1 Nude mouse model [36, 37], 
which mimicked low-dose aspirin use in humans, based 
on profound platelet COX-1 inhibition but an absence of 
systemic COX-2 inhibition, did not increase the sensitiv-
ity of MC38 mouse CRC cell tumours to EPA in vivo, 
in direct contrast to the corresponding in vitro data. We 
demonstrated that there was inefficient inhibition of  PGE2 
production in CRC cell tumour tissue, despite efficient 
systemic COX-1 inhibition. Therefore, a plausible expla-
nation for the lack of aspirin efficacy in vivo is that there 
was incomplete intra-tumoral COX inhibition by aspirin, 
in contrast to the effective dual COX inhibition obtained 
by either genetic deletion or pharmacological inhibition 
in vitro.
Importantly, the mode of administration of aspirin in 
rodent models may affect systemic COX inhibition. Tis-
sue  PGE2 levels in studies comparing oral gavage and 
dietary administration of aspirin and the NSAID sulindac 
are lower after oral gavage, despite equivalent platelet 
COX-1 inhibition, suggesting that the duration and extent 
of tumour COX-2 inhibition in mice are highly dependent 
on the dosing route and schedule [38, 39].
A preliminary observation from the seAFOod polyp pre-
vention trial is that combined treatment with aspirin (300 mg 
once daily) and EPA (2 g FFA daily) reduced colorectal ade-
noma recurrence (as measured by the number of colorectal 
adenomas per participant) to a greater extent than either EPA 
or aspirin alone [6], which is consistent with our in vitro 
observations. Ongoing work is exploring whether aspirin 
use in the seAFOod Trial was associated with significant 
inhibition of systemic and target tissue (rectal mucosa)  PGE2 
synthesis by measuring urinary PGE-M and rectal mucosal 
 PGE2 levels, respectively.
It is recognised that 18R-hydroxyeicosapentaenoic 
acid production by aspirin-acetylated COX-2 can lead to 
5-lipoxygenase-dependent synthesis of E-type resolvins 
(Rv), which have anti-neoplastic activity [40]. The hypoth-
esis that RvE1 and/or RvE2 increase sensitivity of CRC 
cells to EPA is valid and testable in future experiments.
We also conclude that COX-1 and COX-2 modulate 
resistance to EPA by altering sensitivity of CRC cells 
themselves to EPA, rather than by a mechanism including 
enhancement of the host anti-tumour immune response. Our 
data demonstrating that loss of CT26 CRC cell COX expres-
sion has similar effects on the anti-tumour activity of EPA in 
both immunocompetent BALB/c and immunocompromised 
CD1 Nude mice contrast with the study of Zelenay et al., 
in which genetic and pharmacological COX inhibition (in 
this case using the selective COX-2 inhibitor celecoxib) 
reduced CT26 cell tumour growth in immunocompetent, but 
not immunocompromised mice [19]. The difference might 
be due to differences in Nude mice from different colonies. 
Consistent with our data, several other studies have indicated 
that COX inhibition reduces growth of multiple tumour 
types in immunodeficient nude mice [40–43].
The mechanism whereby COX expression drives CRC 
cell resistance to EPA remains unclear. One hypothesis is 
that EPA acts via a COX-independent mechanism(s), which 
is dependent on the intracellular EPA level gained, that is, in 
turn, controlled by the degree of EPA metabolism by COX 
enzymes. The relationship between cellular EPA levels at 
baseline and in response to exogenous EPA in CRC cell 
lines with different levels of COX expression is consist-
ent with this hypothesis. However, pharmacological COX 
inhibition was not associated with increased cellular EPA 
content and there was no discernible relationship between 
COX expression and EPA sensitivity (as measured by the 
MTT assay) across the panel of human CRC cell lines. It is 
possible that a large number of catabolic fates of EPA (via 
multiple oxygenases other than COX, as well as mitochon-
drial beta-oxidation) obscures the contribution of the COX 
enzymes to cellular EPA content and response to supple-
mentation unless there are large changes in COX expression 
and activity as observed in a CRISPR/Cas9 recombination 
model. The intriguing finding that some CRC cells display 
a biphasic concentration–response relationship with EPA 
suggests that EPA has at least two separate mechanisms of 
anti-CRC activity. The observation that genetic loss of, or 
pharmacological inhibition of, COX leads to the emergence 
of a biphasic concentration–response relationship in EPA-
resistant CRC cells suggests that COX activity may ordinar-
ily repress an EPA target in CRC cells that is then unmasked, 
leading to increased CRC cell sensitivity to EPA.
In conclusion, COX activity drives EPA resistance in 
CRC cells providing a clinically relevant opportunity to 
enhance the anti-neoplastic activity of EPA by pharmaco-
logical inhibition of COX using agents already in clinical 
use. The inability of aspirin to enhance the anti-CRC activity 
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of EPA in vivo, in direct contrast to the in vitro data and 
preliminary seAFOod polyp prevention trial observations, 
suggests that the degree of tumour tissue COX inhibition 
achieved by aspirin is likely to be critical for its ability to 
augment the anti-CRC activity of EPA.
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